+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-10-18Number of Pages: 173

Plasma Protease C1-inhibitor Treatment Market (Drug Class- C1-inhibitors (C1-esterase Inhibitor and Recombinant Inhibitor), Kallikrein Inhibitor (Kalbitor), and Selective Bradykinin B2 Receptor Antagonist (Firazyr); Distribution Channel - Hospital Pharmacies and Independent Pharmacies and Outlets; Dosage Type - Lyophilized and Liquid/Injectable) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

1. Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Plasma Protease C1-Inhibitor Treatment Market 

4. Market Overview
      4.1. Introduction
      4.2.  Overview
      4.3. Key Market Indicators
      4.4. Market Dynamics
              4.4.1. Drivers
              4.4.2. Restraints
              4.4.3. Opportunity
      4.5. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, 2015–2025
              4.5.1. Market Revenue Projections (US$ Mn)
      4.7. Porter’s Five Force Analysis
      4.8. Market Outlook
      4.9. Regulatory Scenario
      4.10. Pipeline Analysis and  Patent Launch/Expiry
      4.11. Therapeutic Application & Biological Activities: C1-Esterase Inhibitor
      4.12. Global Number of Procedures of Hereditary Angioedema Disease
      4.13. Brand Analysis Plasma Protease C1-Inhibitor Drugs
      4.14. Product Portfolio of Human C1-INH Plasma Protein
      4.15. Research Institutes Involved In Hereditary Angioedema/Others Disease

5. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, By Drug Class 
      5.1. Introduction & Definition
      5.2. Key Trends
      5.3. Market  Forecast By Drug Class, 2015–2025
              5.3.1. C1-Inhibitor
                        5.3.1.1. C1-Esterase Inhibitor
                        5.3.1.2. Recombinant Inhibitor
              5.3.2. Kallikrein Inhibitor (Kalbitor)
              5.3.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
      5.4. Market Attractiveness By Drug Class 

6. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, By Dosage Type 
      6.1. Introduction & Definition
      6.2. Market  Forecast By Dosage Type, 2015–2025
              6.2.1. Lyophilized
              6.2.2. Liquid/Injectable
      6.3. Market Attractiveness By Dosage Type 

7. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, By Distribution Channel  
      7.1. Introduction & Definition
      7.2. Key Trends
      7.3. Market  Forecast By Distribution Channel , 2015–2025
              7.3.1. Hospital Pharmacies
              7.3.2. Independent Pharmacies and Outlets
      7.4. Market Attractiveness By Distribution Channel  

8. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, By Region
      8.1. Key Findings
      8.2. Market  Forecast By Region
              8.2.1. North America 
              8.2.2. Europe 
              8.2.3. Latin America 
              8.2.4. Rest of World 
      8.4. Market Attractiveness By Country/Region

9. North America Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecast
      9.1. Introduction
              9.1.1. Key Trends
      9.2. Market  Forecast By Drug Class, 2015–2025
              9.2.1. C1-Inhibitor
                        9.2.1.1. C1-Esterase Inhibitor
                        9.2.1.2. Recombinant Inhibitor
              9.2.2. Kallikrein Inhibitor (Kalbitor)
              9.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
      9.3. Market  Forecast By Dosage Type, 2015–2025
              9.3.1. Lyophilized
              9.3.2. Liquid/Injectable      
      9.4. Market  Forecast By Distribution Channel , 2015–2025
              9.4.1. Hospital Pharmacies
              9.4.2. Independent Pharmacies and Outlets
      9.5. Market  Forecast By Country, 2015–2025
              9.5.1. U.S.
              9.5.2. Canada
      9.6. Market Attractiveness Analysis 
              9.6.1. By Drug Class 
              9.6.2. By Dosage Type 
              9.6.3. By Distribution Channel  
              9.6.4. By Country

10. Europe Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecast
      10.1. Introduction
              10.1.1. Key Trends
      10.2. Market Forecast By Drug Class, 2015–2025
              10.2.1. C1-Inhibitor
                        10.2.1.1. C1-Esterase Inhibitor
                        10.2.1.2. Recombinant Inhibitor
              10.2.2. Kallikrein Inhibitor (Kalbitor)
              10.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
      10.3. Market  Forecast By Dosage Type, 2015–2025
              10.3.1. Lyophilized
              10.3.2. Liquid/Injectable
      10.4. Market  Forecast By Distribution Channel, 2015–2025
              10.4.1. Hospital Pharmacies
              10.4.2. Independent Pharmacies and Outlets
      10.5. Market  Forecast By Country, 2015–2025
              10.5.1. EU-5 Countries
              10.5.2. BENELUX Countries
              10.5.3. Rest of Europe
      10.6. Market Attractiveness Analysis 
              10.6.1. By Drug Class 
              10.6.2. By Dosage Type 
              10.6.3. By Distribution Channel  
              10.6.4. By Country

11. Latin America Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecast      
      11.1. Introduction
              11.1.1. Key Trends
      11.2. Market  Forecast By Drug Class, 2015–2025
              11.2.1. C1-Inhibitor
                        11.2.1.1. C1-Esterase Inhibitor
                        11.2.1.2. Recombinant Inhibitor
              11.2.2. Kallikrein Inhibitor (Kalbitor)
              11.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
      11.3. Market  Forecast By Dosage Type, 2015–2025
              11.3.1. Lyophilized
              11.3.2. Liquid/Injectable
      11.4. Market  Forecast By Distribution Channel, 2015–2025
              11.4.1. Hospital Pharmacies
              11.4.2. Independent Pharmacies and Outlets
      11.5. Market  Forecast By Country, 2015–2025
              11.5.1. Argentina
              11.5.2. Brazil
              11.5.3. Rest of Latin America
      11.6. Market Attractiveness Analysis 
              11.6.1. By Drug Class 
              11.6.2. By Dosage Type 
              11.6.3. By Distribution Channel  
              11.6.4. By Country

12. Rest of World Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecast
      12.1. Introduction
              12.1.1. Key Trends
      12.2. Market  Forecast By Drug Class, 2015–2025
              12.2.1. C1-Inhibitor
                        12.2.1.1. C1-Esterase Inhibitor
                        12.2.1.2. Recombinant Inhibitor
              12.2.2. Kallikrein Inhibitor (Kalbitor)
              12.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
      12.3. Market  Forecast By Dosage Type, 2015–2025
              12.3.1. Lyophilized
              12.3.2. Liquid/Injectable
      12.4. Market  Forecast By Distribution Channel, 2015–2025
              12.4.1. Hospital Pharmacies
              12.4.2. Independent Pharmacies and Outlets
      12.5. Market  Forecast By Country, 2015–2025
              12.5.1. Australia
              12.5.2. Israel
              12.5.3. Rest of World Countries
      12.6. Market Attractiveness Analysis 
              12.6.1. By Drug Class 
              12.6.2. By Dosage Type 
              12.6.3. By Distribution Channel  
              12.6.4. By Country

13. Competition Landscape
      13.1. Market Player – Competition Matrix (By Tier and Size of companies)
      13.2. Market Share Analysis By Company (2016)
      13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
              13.3.1. Shire plc
                        13.3.1.1. Overview (HQ, Employee Strength, Business Segments)
                        13.3.1.2. Financials
                        13.3.1.3. Recent Developments
                        13.3.1.4. Strategy
              13.3.2. Pharming Group N.V.
                        13.3.2.1. Overview (HQ, Employee Strength, Business Segments)
                        13.3.2.2. Financials
                        13.3.2.3. Recent Developments
                        13.3.2.4. Strategy
              13.3.3. Sanquin
                        13.3.3.1. Overview (HQ, Employee Strength, Business Segments)
                        13.3.3.2. Financials
                        13.3.3.3. Recent Developments
                        13.3.3.4. Strategy
              13.3.4. CSL Limited
                        13.3.4.1. Overview (HQ, Employee Strength, Business Segments)
                        13.3.4.2. Financials
                        13.3.4.3. Recent Developments
                        13.3.4.4. Strategy

14. Key Take Aways

List of Figures

FIG 01: Global Plasma Protease C1-Inhibitor Treatment Market Size (US$ Mn) Forecast, 2015–2025
FIG 02: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class (2016)
FIG 03: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Region (2016)
FIG 04: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel (2016)
FIG 05: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type (2016)
FIG 06: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
FIG 07: Global Plasma Protease C1-Inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by C1-Inhibitor, 2015–2025
FIG 08: Global Plasma Protease C1-Inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Kallikrein Inhibitor, 2015-2017
FIG 09: Global Plasma Protease C1-Inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Selective Bradykinin B2 Receptor Antagonist, 2015–2025
FIG 10: Global Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
FIG 11: Global Plasma Protease C1-inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
FIG 12: Global Plasma Protease C1-inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Lyophilized, 2015–2025
FIG 13: Global Plasma Protease C1-inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liquid/Injectable, 2015–2025
FIG 14: Global Plasma Protease C1-inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
FIG 15: Global Plasma Protease C1-inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
FIG 16: Global Plasma Protease C1-inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
FIG 17: Global Plasma Protease C1-inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Independent Pharmacies & Outlets, 2015–2025
FIG 18: Global Plasma Protease C1-inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
FIG 19: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Region, 2017 and 2025
FIG 20: Global Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Region, 2017–2025
FIG 21: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
FIG 22: North America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Country, 2017–2025
FIG 23: North America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Country, 2017–2025
FIG 24: North America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
FIG 25: North America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
FIG 26: North America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
FIG 27: North America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
FIG 28: North America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
FIG 29: North America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
FIG 30: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
FIG 31: Europe Plasma Protease C1-Inhibitor Treatment Market Value Share, by Country, 2017–2025
FIG 32: Europe Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Country, 2017–2025
FIG 33: Europe Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
FIG 34: Europe Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
FIG 35: Europe Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
FIG 36: Europe Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
FIG 37: Europe Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
FIG 38: Europe Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
FIG 39: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
FIG 40: Latin America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Country, 2017–2025
FIG 41: Latin America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Country, 2017–2025
FIG 42: Latin America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
FIG 43: Latin America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
FIG 44: Latin America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
FIG 45: Latin America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
FIG 46: Latin America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
FIG 47: Latin America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
FIG 48: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
FIG 49: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value Share, by Country, 2017–2025
FIG 50: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Country, 2017–2025
FIG 51: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
FIG 52: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
FIG 53: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
FIG 54: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
FIG 55: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
FIG 56: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
FIG 57: Global Plasma Protease C1-Inhibitor Treatment Market Share, by Company, 2016 
FIG 58: Breakdown of Net Sales (%), by Therapeutic Area, 2016
FIG 59: Product Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
FIG 60: Breakdown of Net Sales (%), by Major Products, 2016
FIG 61: Sales Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
FIG 62: Breakdown of Net Sales (%), by Therapeutic Area, 2016
FIG 63: Product Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
FIG 64: Breakdown of Net Sales (%), by Europe Region, 2016
FIG 65: Plasma Product Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
FIG 66: Product Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

List of Tables

Table 01: Pipeline Analysis-Phase 3-by Product/Drug Candidate, 2015-2017
Table 02: Pipeline Analysis-Phase 1 & 2 – Preclinical-by Product/Drug Candidate, 2014-2016
Table 03: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
Table 04: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate  
Table 05: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
Table 06: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
Table 07: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
Table 08: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
Table 09: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
Table 10: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
Table 11: Orphan Drug Exclusivity-by Approval & Expiry
Table 12: Orphan Drug Exclusivity-by Approval & Expiry
Table 13: Orphan Drug Exclusivity-by Approval & Expiry
Table 14: Product Portfolio of Human C1-INH Plasma Protein-by Sponsor/Company
Table 15: Global Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 16: Global Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015-2025
Table 17: Global Plasma Protease C1-inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 18: Global Plasma Protease C1-inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 19: Global Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Region, 2015–2025
Table 20: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country, 2015-2025
Table 21: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 22: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
Table 23: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 24: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 25: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 26: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 27: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
Table 28: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 29: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 30: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country,
Table 31: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 32: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
Table 33: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 34: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 35: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 36: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 37: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
Table 38: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
Table 39: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025


 
 
Back To Top